ORIC Pharmaceuticals Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
ORIC Pharmaceuticals's earnings have been declining at an average annual rate of -19.4%, while the Biotechs industry saw earnings growing at 19% annually.
Anahtar bilgiler
-19.4%
Kazanç büyüme oranı
48.3%
EPS büyüme oranı
Biotechs Sektör Büyümesi | 17.0% |
Gelir büyüme oranı | n/a |
Özkaynak getirisi | -36.6% |
Net Marj | n/a |
Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Güncelleme yok
Recent updates
Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation
Aug 21ORIC Pharmaceuticals Stock: Too Early To Justify This Valuation
Jul 29ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield Value
Jul 17We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely
May 08ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains
Mar 13We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate
Jan 18We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Sep 27ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans
Jun 14Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth
Jan 24ORIC Pharmaceuticals: Poster Child For The Current Downturn In Biotech
Oct 14Is ORIC Pharmaceuticals (NASDAQ:ORIC) In A Good Position To Deliver On Growth Plans?
Oct 08ORIC Pharmaceuticals GAAP EPS of -$0.51 beats by $0.09
Aug 11ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans
Jun 24We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely
Mar 08We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Nov 23We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Aug 05ORIC Pharmaceuticals EPS beats by $0.04
May 06Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation
Apr 16We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely
Jan 01Oric Pharma starts expansion phase of mid-stage solid tumor study with ORIC-101
Dec 21Oric Pharma prices stock offering at $23
Nov 13Gelir ve Gider Dağılımı
ORIC Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 24 | 0 | -111 | 27 | 98 |
31 Mar 24 | 0 | -102 | 26 | 88 |
31 Dec 23 | 0 | -101 | 26 | 85 |
30 Sep 23 | 0 | -93 | 24 | 77 |
30 Jun 23 | 0 | -93 | 24 | 69 |
31 Mar 23 | 0 | -90 | 25 | 64 |
31 Dec 22 | 0 | -89 | 25 | 62 |
30 Sep 22 | 0 | -91 | 25 | 62 |
30 Jun 22 | 0 | -85 | 25 | 60 |
31 Mar 22 | 0 | -85 | 24 | 62 |
31 Dec 21 | 0 | -79 | 22 | 57 |
30 Sep 21 | 0 | -84 | 20 | 52 |
30 Jun 21 | 0 | -91 | 18 | 48 |
31 Mar 21 | 0 | -81 | 16 | 40 |
31 Dec 20 | 0 | -74 | 13 | 36 |
30 Sep 20 | 0 | -54 | 11 | 31 |
30 Jun 20 | 0 | -35 | 9 | 28 |
31 Mar 20 | 0 | -30 | 7 | 25 |
31 Dec 19 | 0 | -27 | 6 | 23 |
31 Dec 18 | 0 | -21 | 3 | 19 |
Kaliteli Kazançlar: ORIC is currently unprofitable.
Büyüyen Kar Marjı: ORIC is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: ORIC is unprofitable, and losses have increased over the past 5 years at a rate of 19.4% per year.
Büyüme Hızlandırma: Unable to compare ORIC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: ORIC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Özkaynak Getirisi
Yüksek ROE: ORIC has a negative Return on Equity (-36.63%), as it is currently unprofitable.